ARCHIVES

Zaltrap Economics 101: The Pricing And Repricing of an Expensive Drug

This article is from The Cancer Letter archive.

Vol. 38 No. 43 | November 16, 2012

Download PDF Visit The Full Archive

Related Articles

As For-Profits Provide Phase I Studies, NCI Seeks to Look Deeper and Learn More

April 6, 2012

Dose Adjustments Of Other Drugs Questioned; Underdosing Or Overdosing?

October 15, 2010

NIOSH To Fund 21 Projects With NCI Money

February 25, 1977

IVAX Agreement With Rival BMS Appears To Buttress BMS control of Paclitaxel

November 26, 1999

NDA For MeCCNU Turned Down By Oncologic Drugs Advisory Committee

September 3, 1976

Dietary Interventions Reduce Breast Cancer Risk In Trials

May 27, 2005